Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome and/or undergoing a percutaneous coronary intervention.

Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome and/or undergoing a percutaneous coronary intervention. Kardiol Pol. 2020 Jun 10;: Authors: Mihajlovic M, Marinkovic M, Kozieł M, Mujovic N, Lip GYH, Potpara TS Abstract The use of triple antithrombotic therapy (TAT) consisting of oral anticoagulant (OAC), aspirin and a P2Y12 inhibitor in patients with atrial fibrillation (AF) and an acute coronary syndrome (ACS) and/or a percutaneous coronary intervention (PCI) is associated with high risk of bleeding. Recently, several randomized clinical trials tested the hypothesis that dual antithrombotic therapy (DAT) regimens (consisting of an OAC and a single antiplatelet drug) may be safer regarding bleeding events compared to TAT, also investigating the role of non-vitamin K antagonist oral anticoagulants (NOACs) as a part of DAT and TAT. The purpose of this review article is to provide an overview of available evidence regarding the safety and efficacy of DAT compared to TAT regimens, international guidelines recommendations and knowledge gaps / unmet needs in the management of patients with AF and an ACS and/or PCI. Keywords: acute coronary syndrome, atrial fibrillation, dual antithrombotic therapy, percutaneous coronary. PMID: 32543800 [PubMed - as supplied by publisher]
Source: Polish Heart Journal - Category: Cardiology Authors: Tags: Kardiol Pol Source Type: research